A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.5% in the afternoon session after the stock ...

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

This Nasdaq biotech in my Stocks and Shares ISA portfolio just got a shot in the arm. Here's why I'm almost past caring at this point. The post Up 14% yesterday, is it the end for this train wreck in ...

Durban-headquartered pharmaceutical major Aspen Pharmacare confirmed in a Sens announcement on Friday that it has reached a ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Major stock indexes rose Thursday, as investors digested the latest batch of corporate earnings and China trade news.

Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...

After entering into a definitive agreement to acquire CureVac—who focuses on mRNA-based medicines for oncology and infectious ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...